Although our study provides insights into understanding the potential role of MEG3 in tumor immunology and its use as a cancer biomarker, it is limited in terms of lack of in vitro and in vivo experiments to validate the relationship between MEG3 expression and infiltration of immune cells in gliomas. This evidence concerns the gene MEG3 and neoplasm.